Regulatory T cell depletion via Fc gamma receptor-mediated cytotoxicity

Regulatory T cell depletion via Fc gamma receptor-mediated cytotoxicity" is **not a single molecular target** but rather describes an **immunological process** whereby therapeutic antibodies—such as those targeting CTLA‑4 or GITR—bind to surface antigens highly expressed on intratumoral regulatory T cells. The antibody's constant region then engages activating **Fc gamma receptors** (FcγRs) present on innate immune effector cells such as macrophages and NK cells. This interaction triggers mechanisms like **antibody-dependent cellular cytotoxicity (ADCC)** or **antibody-dependent cellular phagocytosis (ADCP)**, resulting in the selective elimination of these suppressive immune subsets within tumors. This process has been shown preclinically to be essential for the anti-tumor efficacy of certain immunomodulatory antibodies; for example, anti–CTLA‑4 therapy relies heavily on this pathway for depleting intratumoral FoxP3+ regulatory T cells and shifting the balance toward effective anti-tumor immunity[1][3][5]. However, because this is a mechanism rather than a discrete protein or gene product, it should not be considered a canonical drug target per se. In summary: The entry "Regulatory T cell depletion via Fc gamma receptor-mediated cytotoxicity" refers to an important *therapeutic mechanism* used by some cancer immunotherapies but does *not* represent an individual molecular entity suitable for structured database targeting. It is best classified under mechanisms such as ADCC/ADCP mediated by activating FcγRs engaged by therapeutic antibodies bound to specific surface markers on regulatory T cells within tumors[1][6].

Other names

Treg depletion via FcγRRegulatory T cell elimination by Fc gamma receptorAntibody-dependent regulatory T cell cytotoxicity

Engagement of activating Fc gamma receptors on effector cells by the Fc region of therapeutic antibodies bound to regulatory T cells triggers ADCC or ADCP, leading to selective depletion of these cells within the tumor microenvironment[1][5][6].